⭐️🚨Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology @JCO_ASCO @ASCO @Dr_R_Kurzrock @OncoAlert ascopubs.org/doi/10.1200/JCO…

Proud to see @NazliDizman @DanaFarber on the main stage at @SWOG in our GU planning session. Grateful to @PBarataMD @caseccc (PI of S2419, BIOFRONT) & @BraunMDPhD @YaleCancer (GU translational lead) for getting her involved in analyzing biomarker results in the 1st P3 study evaluating microbiome modulation to improve IO-outcomes!

Such an honor to co-chair the WIN symposium with Wafik El Deiry

Living the WIN conference. Molecular Tumor Boards everywhere. Who knew that when we coined the term and concept in 2014, it would take off Iike wild fire!!

Congratulations to my good friend and colleague Mary-Ellen Taplin on the well deserved @PCFnews Women in Science Lifetime Achievement Award ! Thank you @PCF_Science for this important recognition! @DanaFarber_GU @DanaFarber @DanaFarberNews @harvardmed

🚨⭐️What an energizing LIVE molecular tumor board at the WIN Symposium , Providence, RI @WIN_Consortium world‑class precision oncology faculty tackling real & challenging cases in real time @Dr_R_Kurzrock @weldeiry @bickythapa02 @SewantiLimaye ⭐️Imagine if every patient everywhere had access to this level of expert discussion & insight @OncoAlert @oncodaily

The FDA voted in favor of the Galleri blood test for multicancer detection. @DanaFarber's @DrChoueiri tells @GoHealio this is an important milestone, but more long-term data are needed. Read more: bit.ly/4xPVaZh

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

Dr @RashadNawfal is an outstanding prospect for internal medicine residency. He is a superb physician and under his belt he has multi-year laboratory experience in liquid biopsies and epigenomics from my lab and the Freedman lab @DanaFarber @DanaFarber_GU

I’m excited to join fellow experts and Shirley @leung at @BostonGlobe Media’s Future of Medicine Summit to discuss how cancer vaccines are rewriting the rules of treatment – exploring how personalized mRNA vaccines are moving from moonshot ideas to real clinical trials with real patients and real benefits! Join us on September 15 for a day of thought-provoking conversations about what’s next in healthcare. Learn more and register at Globe.com/futureofmedicine. #FutureofMed2026 @DanaFarber @DanaFarber_GU @DanaFarberNews @OnlyInBOS @ScienceinBoston @harvardmed @TheVinodLab #MichelleBrown

So thrilled to have you @neerajaiims with us at @DanaFarber! We are incredibly fortunate to welcome not only an outstanding prostate cancer oncologist, but also a terrific colleague and leader. Excited to see all that you will bring to our team and to the @Harvard Cancer Consortium #ProstateCancer Program. Welcome to @CityOfBoston and to the family! @DanaFarber_GU @harvardmed @DanaFarberNews @df_hcc

Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber 1) Dr. Nazli Dizman @NazliDizman 2) Dr. Brian Russell @brian_russell39 3) Dr. Hamid Emamekhoo @HamidEmamekhoo 4) Pr. Neeraj Agarwal @neerajaiims They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology. Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands. Welcome to @CityOfBoston and @DanaFarber!

The 5-year follow-up from KY-564 now published in @Annals_Oncology --the first ever adjuvant trial in Kidney cancer continues to show a survival benefit now with OS at 5+years and in key subgroups! annalsofoncology.org/article… @HaasNaomi @tompowles1 @OncoAlert @OncBrothers @DanaFarber_GU @DanaFarber @harvardmed @AUC3_Official

Have you ever wondered what takes place in a TCF-001 TRACK Virtual #MolecularTumorBoard meeting? Watch to learn how biomarker testing and multi-disciplinary expertise come together to uncover treatment options for difficult-to-treat #RareCancers targetcancer.short.gy/RCTT-2…

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝘀𝘂𝗯𝗺𝗶𝘁: bit.ly/WINSympo2026website Program spotlight: 𝗪𝗜𝗡 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗧𝘂𝗺𝗼𝗿 𝗕𝗼𝗮𝗿𝗱 At 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲, the WIN International Molecular Tumor Board will bring together multidisciplinary international experts for live case discussions from 𝗪𝗜𝗡 𝗖𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺 institutions, with audience participation encouraged. The tumor board will be chaired by 𝗗𝗿. 𝗥𝗮𝘇𝗲𝗹𝗹𝗲 𝗞𝘂𝗿𝘇𝗿𝗼𝗰𝗸, 𝗠𝗗, 𝗙𝗔𝗖𝗣, WIN Consortium, Chevilly-Larue, France, and Medical College of Wisconsin, Milwaukee, WI, USA. Co-chairs include 𝗗𝗿. 𝗪𝗮𝗳𝗶𝗸 𝗘𝗹-𝗗𝗲𝗶𝗿𝘆, 𝗠𝗗, 𝗣𝗵𝗗, 𝗙𝗔𝗖𝗣, WIN Consortium, Chevilly-Larue, France, and Brown University Health, Providence, RI, USA; and 𝗗𝗿. 𝗦𝗲𝘄𝗮𝗻𝘁𝗶 𝗔. 𝗟𝗶𝗺𝗮𝘆𝗲, 𝗠𝗕𝗕𝗦, 𝗠𝗗, 𝗠𝗦, WIN Consortium, Chevilly-Larue, France, and Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai, India. Panelists include 𝗗𝗿. 𝗚𝗶𝘂𝘀𝗲𝗽𝗽𝗲 𝗖𝘂𝗿𝗶𝗴𝗹𝗶𝗮𝗻𝗼, 𝗠𝗗, 𝗣𝗵𝗗; 𝗗𝗿. 𝗩𝗶𝘃𝗲𝗸 𝗦𝘂𝗯𝗯𝗶𝗮𝗵, 𝗠𝗗; 𝗗𝗿. 𝗚𝗶𝘀𝗲𝗹𝗹𝗲 𝗟. 𝗦𝗮𝘂𝗹𝗻𝗶𝗲𝗿 𝗦𝗵𝗼𝗹𝗹𝗲𝗿, 𝗠𝗗; 𝗮𝗻𝗱 𝗗𝗿. 𝗕𝗶𝗰𝗸𝘆 𝗧𝗵𝗮𝗽𝗮, 𝗠𝗗, 𝗠𝗦, 𝗙𝗔𝗖𝗣. 𝗣𝗼𝘀𝘁𝗲𝗿 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗰𝗹𝗼𝘀𝗲𝘀 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟭, 𝟮𝟬𝟮𝟲. Register now and submit your abstract by the deadline. WIN Symposium 2026, 𝗲𝗻𝗱𝗼𝗿𝘀𝗲𝗱 𝗯𝘆 𝗔𝗦𝗖𝗢®, will take place 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮-𝟯, 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗥𝗵𝗼𝗱𝗲 𝗜𝘀𝗹𝗮𝗻𝗱, 𝗨𝗦𝗔. #WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #MolecularTumorBoard ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝘀𝘂𝗯𝗺𝗶𝘁: bit.ly/WINSympo2026website 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 for 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 closes on 𝗔𝘂𝗴𝘂𝘀𝘁 𝟭𝟲, 𝟮𝟬𝟮𝟲. 𝗣𝗼𝘀𝘁𝗲𝗿 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 has been extended to 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟭, 𝟮𝟬𝟮𝟲. Explore 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆. This session will highlight translational research, clinical trial design, novel therapies and the application of precision oncology across cancer types. Session speakers include: > 𝗗𝗿. 𝗚𝗶𝘂𝘀𝗲𝗽𝗽𝗲 𝗖𝘂𝗿𝗶𝗴𝗹𝗶𝗮𝗻𝗼, 𝗠𝗗, 𝗣𝗵𝗗 University of Milano / European Institute of Oncology, Milan, Italy | President-Elect, ESMO 2027-2028 > 𝗗𝗿. 𝗕𝗲𝗻𝗲𝗱𝗶𝘁𝗼 𝗔. 𝗖𝗮𝗿𝗻𝗲𝗶𝗿𝗼, 𝗠𝗗, 𝗠𝗦 Legorreta Cancer Center, Brown University, Providence, RI, USA > 𝗗𝗿. 𝗝𝗲𝗻𝗻𝗶𝗳𝗲𝗿 𝗚𝗿𝗮𝗻𝗱𝗶𝘀, 𝗠𝗗 University of California San Francisco, San Francisco, CA, USA > 𝗗𝗿. 𝗞𝗼𝗿𝗻𝗲𝗹𝗶𝗮 𝗣𝗼𝗹𝘆𝗮𝗸, 𝗠𝗗, 𝗣𝗵𝗗 Harvard Medical School / Dana-Farber Cancer Institute, Boston, MA, USA 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 is endorsed by ASCO®*, supporting the scientific positioning of this year’s program. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝘆 𝗔𝘂𝗴𝘂𝘀𝘁 𝟭𝟲 𝘁𝗼 𝘀𝗲𝗰𝘂𝗿𝗲 𝘁𝗵𝗲 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝗿𝗮𝘁𝗲. 𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗽𝗼𝘀𝘁𝗲𝗿 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝗯𝘆 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟭. #WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #ClinicalResearch *ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.

Breathtaking line up including Nobel Laureate. And Rhode Island is stunning

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝘀𝘂𝗯𝗺𝗶𝘁: bit.ly/WINSympo2026website 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 for 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 closes on 𝗔𝘂𝗴𝘂𝘀𝘁 𝟭𝟲, 𝟮𝟬𝟮𝟲. 𝗣𝗼𝘀𝘁𝗲𝗿 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 has been extended to 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟭, 𝟮𝟬𝟮𝟲. Explore 𝗙𝗿𝗼𝗺 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘁𝗼 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 - 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗱 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. This session will examine how precision oncology is moving from molecular insight to clinical delivery, with discussion spanning molecular profiling, N-of-1 oncology, bedside-to-bench translational research, rational combination therapies and regulatory innovation. Session speakers include: > 𝗗𝗿. 𝗥𝗮𝘇𝗲𝗹𝗹𝗲 𝗞𝘂𝗿𝘇𝗿𝗼𝗰𝗸, 𝗠𝗗, 𝗙𝗔𝗖𝗣 WIN Consortium, Chevilly-Larue, France & Medical College of Wisconsin, Milwaukee, WI, USA > 𝗗𝗿. 𝗞𝗲𝗶𝘁𝗵 𝗧. 𝗙𝗹𝗮𝗵𝗲𝗿𝘁𝘆, 𝗠𝗗, 𝗙𝗔𝗔𝗖𝗥 Massachusetts General Hospital / Harvard Medical School, USA | AACR President, Boston, MA, USA > 𝗗𝗿. 𝗥𝗶𝗰𝗵𝗮𝗿𝗱 𝗣𝗮𝘇𝗱𝘂𝗿, 𝗠𝗗 Former Director, FDA Oncology Center of Excellence, Washington, USA Chaired by 𝗗𝗿. 𝗥𝗮𝘇𝗲𝗹𝗹𝗲 𝗞𝘂𝗿𝘇𝗿𝗼𝗰𝗸, 𝗠𝗗, 𝗙𝗔𝗖𝗣 and 𝗗𝗿. 𝗪𝗮𝗳𝗶𝗸 𝗦. 𝗘𝗹-𝗗𝗲𝗶𝗿𝘆, 𝗠𝗗, 𝗣𝗵𝗗, 𝗙𝗔𝗖𝗣. WIN Symposium 2026 is endorsed by American Society Of Clinical Oncology®*, supporting the scientific positioning of this year’s program. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝘆 𝗔𝘂𝗴𝘂𝘀𝘁 𝟭𝟲 𝘁𝗼 𝘀𝗲𝗰𝘂𝗿𝗲 𝘁𝗵𝗲 𝗘𝗮𝗿𝗹𝘆 𝗕𝗶𝗿𝗱 𝗿𝗮𝘁𝗲. 𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗽𝗼𝘀𝘁𝗲𝗿 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝗯𝘆 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟭. #WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #TranslationalResearch *ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.

We are proud to announce that #WINSympo2026 is endorsed by @ASCO “Precision Oncology: Innovation and Equity Across the Globe”, October 2-3, 2026, Providence, Rhode Island, USA Register here: mcigroup-winsymposium2026.ev…

𝗩𝗶𝗲𝘄 𝘁𝗵𝗲 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗮𝗻𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿: bit.ly/WINSympo2026website 𝗡𝗲𝘄 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗮𝗻𝗱 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝗳𝗼𝗿 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲. 𝗪𝗜𝗡 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟲 is endorsed by 𝗔𝗦𝗖𝗢®, supporting the scientific positioning of this year’s program. Taking place 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮-𝟯, 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗥𝗵𝗼𝗱𝗲 𝗜𝘀𝗹𝗮𝗻𝗱, 𝗨𝗦𝗔, WIN Symposium 2026 will bring together an international faculty of leaders across oncology, precision medicine, translational science, AI and data science, radiation oncology, rare cancers, global collaboration, and clinical implementation. This year’s program will explore: 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗘𝗾𝘂𝗶𝘁𝘆 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗚𝗹𝗼𝗯𝗲 New speaker highlights include: 𝗗𝗿. 𝗩𝗶𝘃𝗲𝗸 𝗦𝘂𝗯𝗯𝗶𝗮𝗵, 𝗠𝗗 - Keynote speaker, with a focus on precision oncology in practice, including early detection, rare and complex cancers, and tumor-agnostic approaches 𝗗𝗿. 𝗖𝗵𝗮𝗿𝗹𝗲𝘀 𝗕𝗮𝗹𝗰𝗵, 𝗠𝗗 - Global precision oncology, access, equity, and international collaboration 𝗗𝗿. 𝗬𝘃𝗲𝘀 𝗟𝘂𝘀𝘀𝗶𝗲𝗿, 𝗠𝗗 - Artificial intelligence and data science in precision oncology 𝗗𝗿. 𝗕𝗲𝗻𝗲𝗱𝗶𝘁𝗼 𝗔. 𝗖𝗮𝗿𝗻𝗲𝗶𝗿𝗼, 𝗠𝗗, 𝗠𝗦 - Translational oncology 𝗗𝗿. 𝗗𝗮𝘃𝗶𝗱 𝗦𝗽𝗲𝘁𝘇𝗹𝗲𝗿, 𝗠𝗗 - AI, genomic profiling, and the changing frontier of precision medicine 𝗗𝗿. 𝗦𝘁𝗲𝗽𝗵𝗲𝗻 𝗖𝗵𝘂𝗻, 𝗠𝗗 - Radiation oncology and checkpoint immunotherapy 𝗗𝗿. 𝗝𝗮𝗰𝗼𝗯 𝗦𝗰𝗼𝘁𝘁, 𝗠𝗗 - Personalized medicine in radiation oncology 𝗗𝗿. 𝗘𝘆𝘁𝗮𝗻 𝗥𝘂𝗽𝗽𝗶𝗻, 𝗠𝗗, 𝗣𝗵𝗗 - Fast and accessible precision oncology 𝗗𝗿. 𝗕𝗶𝗰𝗸𝘆 𝗧𝗵𝗮𝗽𝗮, 𝗠𝗗 - Rare genitourinary cancers in the precision era Join the international precision oncology community in Providence for two days of scientific exchange, collaboration, and discussion. *@ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event. #WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #TranslationalResearch